Clinical Trial to Evaluate the Efficacy and Safety of the Use of Ozone Versus Sunflower Oil in Treating Diabetic Foot

Overview

This is a open, phase III, multicenter, prospective, comparative, controlled, randomized clinical trial to evaluate the efficacy and safety of the use of ozone released by Philozon Medplus device versus conventional therapy in treating patients with diabetic foot.

Full Title of Study: “Clinical Trial, Open, Phase III, Multicenter, Randomized to Evaluate the Efficacy and Safety of the Use of Ozone Released by Philozon Medplus Device Versus Conventional Therapy in Treating Patients With Diabetic Foot.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2012

Detailed Description

– Clinical trial, open, phase III, multicenter, prospective, comparative, controlled, randomized to evaluate the efficacy and safety of the use of ozone released by Philozon Medplus device versus conventional therapy in treating patients with diabetic foot. – Primary Objective: evaluate the efficacy and safety of ozone released by the device Philozon Medplus in the treatment of patients with diabetic foot. – Secondary objective: evaluate ozone analyzer by environmental ozone Philozon Medplus released by the device in the clinical setting after using the device for rectal insufflation in a patient with diabetic foot. – Study population: Patients of both sexes, consisting of 100 patients over 18 years, patients with diabetic foot. – Treatment: 50 patients receive ozone therapy (topical and rectal insufflation of ozone). 50 patients will receive conventional treatment (Sunflower Oil).

Interventions

  • Other: sunflower oil
    • The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
  • Other: Ozone Therapy
    • The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.

Arms, Groups and Cohorts

  • Experimental: Ozone therapy
    • The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
  • Active Comparator: sunflower oil
    • The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present. Other Names: Sunflower oil

Clinical Trial Outcome Measures

Primary Measures

  • Evaluate the efficacy and safety of ozone released by the device Philozon Medplus in the treatment of patients with diabetic foot.
    • Time Frame: 65 days
    • Evaluate the efficacy and safety of the release of ozone Medplus Philozon device in the treatment of patients with diabetic foot, through the clinical evaluation by the investigator based on the time needed for healing and decreasing the larger diameter of the lesion to be accompanied by image (photo), which register the size of the lesion in centimeters with a ruler.

Secondary Measures

  • Evaluate the release of ozone in the environment by equipment MEdplus after insufflation rectal in patients with diabetic foot.
    • Time Frame: 65 days
    • Evaluate using ozone analyzer environmental ozone released by the device Philozon Medplus in the clinical setting after using the device for rectal insufflation in a patient with diabetic foot.

Participating in This Clinical Trial

Inclusion Criteria

  • Consent form signed; – Patients with Diabetes Mellitus Type I or Type II trophic lesions presenting in the lower limbs; – Injury whose largest diameter is less than 5 cm; – Patients of both sexes, aged above 18 years; – Heart rate 60 to 100 bpm. Exclusion Criteria:

  • Presence of severe septic conditions; – IMC > 30; – Presence of Lymphedema; – Presence of trophic lesions in the lower limbs: exudative, traumatic and parasitic; – Trophic lesions caused by venous disease requiring treatment; – Hepatic or renal dysfunction; – History of alcohol abuse and drugs in the last 6 months; – Laboratory parameters: – hemoglobin < 10 g/dl; – Glycated hemoglobin > 9%; – Diagnosis of hyperthyroidism (TSH < 0.50 μUI/mL, free T4 > 1.80 ng/dL); – Deficit of Glucose 6 Phosphate Dehydrogenase (G6PD) > 20%; – Use of immunosuppressive drugs or anticonvulsants; – Pregnant woman or lactating; – Any significant medical condition which in the opinion of the Investigator may bring risks to the patient; – Known hypersensitivity to drugs and/or treatments to be used in the study; – Inability to compliance with the protocol; – Participation in another clinical trial for less than 30 days.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Philozon Geradores de Ozonio LTDA
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Luiz L Pfluck, Investigator, Principal Investigator, Pronto Socorro de Fraturas
    • Marcelo C Burihan, Investigator, Principal Investigator, Hospital Santa Marcelina
    • Renato t Santos, Investigator, Principal Investigator, Associação Hospitalar Beneficente São Vicente de Paulo
  • Overall Contact(s)
    • Renato T Santos, Investigator, 5554-3312-2099, renatotadeus@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.